1. Conférence de Consensus. Conclusions et recommandations du jury. Texte de Consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1998;22 : S275-88. 2. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089. J Clin Oncol 2003; 21:2912-2919. 3. TNM classification of malignant tumours. UICC 6 th edition 2002. Sobin LH and Wittekind C ed. New York:Wiley-Liss;2002. 4. bis AJCC Cancer Staging Manual, 6 th ed. New York (NY): Springer; 2002. 5. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-1425. 6. Prise en charge thérapeutique des métastases hépatiques des cancers colorectaux. Recommandations pour la pratique clinique. Gastroenterol Clin Biol 2003 ; 27, HS2 : B14-B15. 7. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut 2002; 51:65-69. 8. Buyse M, Piedbois P. Should DUKES’B patients recieve adjuvant therapy ? A statistical perspective ; Sem Oncol 2001 ; 1 , suppl 1 : 20-24. 9. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17:1349-1355. 10. Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum and the Meta-Analysis Group in Cancer. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22:484-492. 11. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepard L, Zee B, et al International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17:1356-1363. 12. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-1806. 13. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004; 22:3395-3407. 14. Gray RJ, Barnwell J, Hills R, McConkey C, Williams W, Kerr D et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients (abstract 3501). Proc Am Soc Clin Oncol 2004; 24; 246. 15. Hickish T, Boni C, Navarro M, Tabernero J, Bonetti A, Clingan P et al. Stage II patients in the “MOSAIC” trial evaluating oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis(abstract 284P). Ann Oncol 2004; 15 (suppl 3): iii76 16. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-3419. 17. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005 ; 352 : 2696-2704. 18. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-2064. 19. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, et al. GIVIO-SITAC 01 : a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma -- Long term results and evaluation of the indicators of health-related quality of life. Cancer 1998 ; 82:2135-44. 20. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995 ; 345:939-44. 21. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994 ;106:899-906. 22. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997 ;15:246-50. 23. Moertel CG, Fleming TR, Mac Donald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8. 24. QUASAR Collaborative Group. Comparison on fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer : a randomised trial. Lancet 2000 ; 355 : 1588-1596. 25. Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin, and levamisol in high-risk stage II and III colon cancer : final report of Intergroup 0089. J Clin Oncol 2005 ; 23 : 8671-8 26. André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al. For the GERCOR Group, Paris France. Bimonthly Regimen of 5-Fluorouracil and Leucovorin (LV5FU2) as Adjuvant Therapy in Stage II and III Côlon Cancer: 4-Year Results of a Randomized Trial. J Clin Oncol 2003, 21:2896-903. 27. André T, Quinaux E, Louvet C, Gamelin E, Bouche O, Achille E, et al. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients (abstr 3576). J Clin Oncol 2005; 23 (Sup 16S): 251s 28. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment of colon cancer. N Engl J Med 2004; 350:2343-2351. 29. de Gramont A., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years (abstr 3501) . J Clin Oncol 2005;23 (Sup 16S): 246s . 30. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith RE. A Phase III comparing FULV to FULV + oxaliplatin in stage II and III colon cancer: Results of the NSABPC07 protocol (abstract 3500). J Clin Oncol 2005;23 (Sup 16S) :246s 31. Sargent D. J., Wieand S., Haller D. G., Buyse M, Labianca R, Benedetti J et al. Disease-free Survival (DFS) vs. Overall Survival (OS) as a Primary Endpoint for Adjuvant Colon Cancer Studies: Individual patient data from 20,898 patients on 18 Randomized Trials. J Clin Oncol 2005; sous presse. 32. Saltz LB, Niedzwiecki D, Hollis D, Goldberg R, Hantel A, Thomas JP et al. Irinotecan plus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) (abstract 3500) . Proc Am Soc Clin Oncol 2004;22:246s. 33. Ychou M, Raoul JL, Douillard JY, Bugat R, Mineur L, Viret F et al. A phase III trial of LV5FU2 + CPT-11 vs LV5FU2 alone in adjuvant high risk colon cancer (FNLCC Accord02/FFCD9802) (abstract 3502) . J Clin Oncol 2005;23 (Sup 16S):246s. 34. Van Cutsem E, Labianca R, Hossfeld D, Bodoky G, Roth A, Aranda E.B. et al. Randomized Phase III Trial Comparing Infused Irinotecan/5-Fluorouracil (5-FU)/ Folinic Acid (IF) versus 5-FU/FA (F) in Stage III Colon Cancer Patients (PETACC-3; V307) (abstract 8) . J Clin Oncol 2005 ;23 (Sup 16S): 3s. 35. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-7. 36. Parc Y, Gueroult S, Mourra N, Serfaty L, Flejou JF, Tiret, Parc R. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53:371-375. 37. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-257. 38. Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006 ; 13 : 766-767. 39. Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C, Purdie CA, Piris J, Morris R, Harrison DJ, Paty PB, Culliford A, Romans KE, Montgomery EA, Choti MA, Kinzler KW, Vogelstein B. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002 ; 359 : 219-225. 40. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004 ; 22 : 1564-1571. 41. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960-1964. 42. A. Carrato, C. Köhne, L. Bedenne, I. Popov, O. Bouche, E. Gaspar, P. Rougier, U. Schubert, F. Biertz, H. Becker, for AIO/CAO, FFCD, TTD, EORTC. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. J Clin Oncol, 2006 ASCO ; 24 (18S) : 3563